Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allergy Therapeutics's change in inventory for the quarter that ended in Dec. 2025 was $0.35 Mil. It means Allergy Therapeutics's inventory
declined by $0.35 Mil
from Jun. 2025 to Dec. 2025 .
Allergy Therapeutics's change in inventory for the fiscal year that ended in Jun. 2025 was $-1.38 Mil. It means Allergy Therapeutics's inventory
increased by $1.38 Mil
from Jun. 2024 to Jun. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Allergy Therapeutics's Days Inventory for the quarter that ended in Dec. 2025 was 171.94.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Allergy Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.06.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Allergy Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.38.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Allergy Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics Change In Inventory Related Terms
Allergy Therapeutics Change In Inventory Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-2.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-2.04 Mil mean?
Allergy Therapeutics (AGYTF) has a Change In Inventory of $-2.04 Mil as of Dec. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' Change In Inventory too high?
Allergy Therapeutics' current Change In Inventory is $-2.04 Mil. Overall, Allergy Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' Change In Inventory compare to ZTS and UTHR?
Allergy Therapeutics' Change In Inventory of $-2.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Allergy Therapeutics and its competitors. Allergy Therapeutics's current Change In Inventory is $-2.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (AGYTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.15 — trading 400% above its estimated fair value. The current Change In Inventory is $-2.04 Mil. Allergy Therapeutics' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Allergy Therapeutics (AGYTF), the current Change In Inventory is $-2.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Allergy Therapeutics (AGYTF) Overvalued in 2026?
Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued.
The current stock price of $0.15 is trading 400% above its estimated GF Value™ of $0.03.
GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.
Key valuation signals for AGYTF:
Change In Inventory: $-2.04 Mil
GF Value™: $0.03 vs. price of $0.15 (400% above fair value)
No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
24GF Score
Get the complete analysis for AGYTF
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGYTF has been successfully added to your 
